Navigation Links
Varian Medical Systems Schedules Fiscal Year End Review for Investors in New York
Date:10/18/2011

PALO ALTO, Calif., Oct. 18, 2011 /PRNewswire/ -- Varian Medical Systems (NYSE: VAR) announced today that its management will hold a fiscal year 2011 review for investors on November 3, 2011 at the Concierge Conference Center, 780 Third Avenue, New York, from 11:30 a.m. ET to 1:00 p.m. ET.

Management will include Tim Guertin, President and CEO; Dow Wilson, Executive Vice President and Chief Operating Officer; Kolleen Kennedy, Senior Vice President and President of Oncology Systems; Robert Kluge, Senior Vice President and President of X-Ray Products; Elisha Finney, Senior Vice President and CFO; Lester Boeh, Vice President Emerging Businesses; and Spencer Sias, Vice President, Investor Relations.

You may RSVP by contacting Anne Rambo at (650) 424-5834, or email: anne.rambo@varian.com.  

The meeting will be webcast and may be accessed via: www.varian.com/investor

Web conferences will be archived on the company website for a year.  Additional information about Varian Medical Systems can be obtained on the company's website.  Investors can subscribe to receive automatic "e-mail alerts" regarding Varian news and events via the company website at www.varian.com/investor.

Varian Medical Systems, Inc., of Palo Alto, California, is the world's leading manufacturer of medical devices and software for treating cancer and other medical conditions with radiotherapy, radiosurgery, and brachytherapy. The company supplies informatics software for managing comprehensive cancer clinics, radiotherapy centers and medical oncology practices. Varian is a premier supplier of tubes and digital detectors for X-ray imaging in medical, scientific, and industrial applications and also supplies X-ray imaging products for cargo screening and industrial inspection. Varian Medical Systems employs approximately 5,700 people who are located at manufacturing sites in North America, Europe, and China and approximately 70 sales and support offices around the world. For more information, visit http://www.varian.com or follow us on Twitter.

FOR INFORMATION CONTACT:
Spencer Sias, (650) 424-5782
Vice President, Corporate Communications
and Investor Relations
spencer.sias@varian.com


'/>"/>
SOURCE Varian Medical Systems
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. First Patient Enrolled in Europe in Ovature Phase III Ovarian Cancer Trial
2. Sunesis Pharmaceuticals Reports Preliminary SNS-595 Activity in Ovarian Cancer Clinical Trial at AACR-NCI-EORTC International Conference
3. Clinical Studies of OvaRex in Advanced Ovarian Cancer Fail to Meet Primary Endpoint
4. Northwest Biotherapeutics Conducting Ovarian Cancer Clinical Trial With DCVax(R)-L at University of Pennsylvania
5. EntreMed Commences Phase 2 Study With MKC-1 in Ovarian/Endometrial Cancers
6. BioNumerik Commences Global Phase III Ovarian Cancer Trial on Novel Anticancer Drug Candidate Known as Karenitecin(R)
7. Sunesis Pharmaceuticals Reports Positive Interim Data for SNS-595 Single-Agent Activity in Platinum-Resistant Ovarian Cancer
8. Vermillions Biomarkers Prove Beneficial in Identifying Women With Ovarian Cancer and Detecting Early-Stage Disease
9. BSI-201 Demonstrates Significant Tumor Growth Inhibition and Increased Survival Rates in Preclinical Ovarian Cancer Studies
10. BiPar Sciences Expands Phase 2 Clinical Trials of BSI-201, a Novel DNA Repair Inhibitor, in Ovarian Cancer
11. Join NPRs David Ewing Duncan, Author Jessica Queller and a Panel of Medical and Legal Experts in a 90-Minute Webcast on Genetic Testing, Genomic Medicine and Breast & Ovarian Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/20/2017)... , April 20, 2017 Research ... America Pharmaceutical Contract Manufacturing Services Market Analysis By Service (Manufacturing, ... Segment Forecasts, 2014 - 2025" report to their offering. ... The Latin American ... 21.0 billion by 2025 Low drug registration cost ...
(Date:4/19/2017)... Cardiology devices segment is anticipated to reach the highest market ... segment is likely to create absolute $ opportunity of a ... By the end of 2027, Cardiology Devices segment is projected ... expanding at a CAGR of 18.4% over the forecast period. ... reprocessed medical devices market in terms of revenue ...
(Date:4/19/2017)... April 19, 2017  IRIDEX Corporation (Nasdaq: ... results for the first quarter 2017 after the close ... management team will host a corresponding conference call beginning ... Investors interested in listening to the conference call ... callers or (703) 326-3030 for international callers, using conference ...
Breaking Medicine Technology:
(Date:4/21/2017)... , ... April 21, 2017 , ... Providing broad access ... in opposition, but there is a better way to address this problem. , That ... of Pharmacy, Public Policy and Economics at the University of Southern California, who served ...
(Date:4/21/2017)... ... April 21, 2017 , ... Chicago plastic surgeon, ... of osteoma. An osteoma is a benign bony lump located on the forehead usually ... can cause difficulties with sight and pain. Dr. Shah has discovered an approach that ...
(Date:4/21/2017)... , ... April 21, 2017 , ... ... Allegheny County that offers services to communities throughout the greater Pittsburgh metropolitan region, ... charity drive to provide adaptive bicycles for differently-abled children. , Variety the Children’s ...
(Date:4/21/2017)... ... , ... The Patient Advocacy Community of The Beryl Institute presented Eve DeVaro, ... Patient Advocacy Award in recognition of her extraordinary contributions to the field of ... The Beryl Institute’s annual Patient Experience Conference on March 20 in Denver, ...
(Date:4/21/2017)... ... April 21, 2017 , ... ... partnered with O2X , an active lifestyle company that provides Human Performance ... health of firefighters, police offers, first responders, military officers and others in service ...
Breaking Medicine News(10 mins):